June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Efficacy of Rebamipide in an Endotoxin-Induced Uveitis Model
Author Affiliations & Notes
  • Akira Takamiya
    Ophthalmology, Asahikawa Medical Unversity, Asahiawa, Japan
  • Harumasa Yokota
    Ophthalmology, Asahikawa Medical Unversity, Asahiawa, Japan
  • Akito Shimouchi
    Ophthalmology, Asahikawa Medical Unversity, Asahiawa, Japan
  • Akitoshi Yoshida
    Ophthalmology, Asahikawa Medical Unversity, Asahiawa, Japan
  • Footnotes
    Commercial Relationships Akira Takamiya, None; Harumasa Yokota, None; Akito Shimouchi, Ezaki Glico Co. (F); Akitoshi Yoshida, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5372. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Akira Takamiya, Harumasa Yokota, Akito Shimouchi, Akitoshi Yoshida; Efficacy of Rebamipide in an Endotoxin-Induced Uveitis Model. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5372. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To determine if rebamipide treatment suppresses the retinal inflammatory response in an endotoxin-induced uveitis (EIU) murine model by injection of lipopolysaccharide (LPS).

Methods: Uveitis was induced by intraperitoneal injection of LPS (Sigma Aldrich) in adult wild-type mice 24 hours after a sub-Tenon injection of 2% rebamipide ophthalmic suspension (rebamipide group) or phosphate buffered saline (control group). Retinal cross-sections were prepared on days 1, 3, and 7 after LPS treatment, and immunohistochemistry was performed using anti-glial fibrillary acidic protein (GFAP) antibody, anti-phosphorylated ERK antibody, and anti-phosphorylated STAT3 antibody to histologically determine the efficacy of rebamipide in the EIU model.

Results: The GFAP expression increased in both groups on days 1 and 3 after LPS treatment, but the expression in the rebamipide group was suppressed in the retina compared with that in the control group. However, phosphorylation of EPK and STAT3 in the retina was seen in both groups. The phosphorylation also was suppressed in the rebamipide group compared to the control group.

Conclusions: Our results suggested that rebamipide may play a role in suppression of the inflammatory response in the retina in an EIU murine model.

Keywords: 746 uveitis-clinical/animal model • 557 inflammation • 603 Muller cells  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.